abstract |
The present invention relates to dopamine receptors (eg D 1 , D 2 , D 3 , D 4 and D 5 ), in particular ligands (eg agonists, antagonists and partial agonists) to D 1 , D 2 , and D 3 dopamine receptors. Relates to compounds designed as The invention also relates to methods for the rational design of these compounds and therapeutic methods using these compounds. |